Sun Pharmaceutical Industries Ltd Share Price Today - Sun Pharmaceutical Industries Ltd Stock Price Live NSE/BSE

Sun Pharmaceutical Industries Ltd

NSE: SUNPHARMA BSE: 524715

₹1825.30

(-0.03%)

Thu, 12 Mar 2026, 11:28 pm

MTF 5xInvest in Sun Pharmaceutical Industries Ltd with 5x Leverage Buy with MTF

Market Cap4378.44B

PE Ratio40.12

Dividend0.90

Health Technology

Pharmaceuticals: Major

24.5K

Sun Pharmaceutical Industries Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
437854.64
Net Profit
10980.10
P/B
5.77
Sector P/E
32.85
P/E
38.10
EV/EBITDA
24.60
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
16.16
ROCE
19.52
Debt/Equity
0.04
EPS (TTM)
50.61
Dividend Yield
0.88
Book Value
324.34
Interest Cover
60.44

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.9x coverage).
Dividends after 3 years are expected to be well covered by earnings (6.3x coverage).
Sun Pharmaceutical Industries's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Sun Pharmaceutical Industries's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Sun Pharmaceutical Industries's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Sun Pharmaceutical Industries is expected to increase but not above the 50% threshold in 2 years time.
Sun Pharmaceutical Industries's earnings are expected to grow by 17.5% yearly, however this is not considered high growth (20% yearly).
Sun Pharmaceutical Industries's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	54.48	54.48	54.48	54.48	54.48
FII	16.12	16.55	17.26	17.96	18.05
DII	20.82	20.23	19.50	18.70	18.55
Public	8.58	8.73	8.77	8.87	8.92
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

70.29

MACD

31.85

50 DMA

1712.70

200 DMA

1690.78

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	2110.80	1908.60	1822.80	1706.40	1620.60	1504.20	1302.00
Fibonacci	1908.60	1831.36	1783.64	1706.40	1629.16	1581.44	1504.20
Camarilla	1792.61	1774.07	1755.54	1706.40	1718.46	1699.93	1681.39

Pivots Level: Classic

+404.40

2110.80

+202.20

1908.60

+116.40

1822.80

1706.40

Pivot Point

LTP: 1825.30

-85.80

1620.60

-202.20

1504.20

-404.40

1302.00

Moving Average

SMAEMA

Period

Value

10-EMA
1792.03
20-EMA
1764.00
30-EMA
1748.28
50-EMA
1734.44
100-EMA
1720.69
200-EMA
1708.56

Announcement Date	Purpose	Action	Ex Date
31 Jan 2026	board-meetings	Quarterly Results, Interim Dividend
31 Jan 2026	dividend	₹11.00 Dividend /Share	05 Feb 2026
05 Jan 2026	dividend	Interim Dividend - Rs. - 11	05 Feb 2026
05 Nov 2025	board-meetings	Quarterly Results
07 Jun 2025	dividend	Final Dividend - Rs. - 5.5	07 Jul 2025
22 May 2025	agm
22 May 2025	dividend	₹5.50 Dividend /Share	07 Jul 2025
31 Jan 2025	dividend	₹10.50 Dividend /Share	06 Feb 2025
06 Jan 2025	dividend	Interim Dividend - Rs. - 10.5	06 Feb 2025
10 Dec 2024	egm

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Cipla Ltd

Lupin Ltd

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd About

Sun Pharmaceuticals Industries is engaged in the business of manufacturing developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical ingredients (APIs). The Company has various manufacturing locations spread across the country with trading and other incidental and related activities extending to the global market.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1993

Headquarters

CEO

Dilip S Shanghvi

Employees

Contact

Website

http://www.sunpharma.com

secretarial@sunpharma.com

Phone

91-265-6615500

Location

Sun Pharma Advanced Res.Centre, Tandalja, Vadodara, Gujarat, 390020

Year	History
2020	Launched FluGuard (Favipiravir) in India at Rs. 35 per tablet. Introduced ABSORICA LD Capsules for severe recalcitrant nodular acne in the US.
2021	Launched website for Long Term Care Portfolio in the US. Launched Sunkalp on National Doctors' Day. Launched Chericof 12 in India for 12-hour cough relief.
2022	Entered license agreement with SPARC for commercialization of phenobarbital for injection in the US. Expanded license and supply agreements with Cosmo for WINLEVI to include Japan. Launched CEQUA, first dry eye treatment with nanomicellar technology, in Canada. Obtained exclusive patent license from Lundbeck to introduce Vortioxetine in India. Acquired Uractiv Portfolio from Fiterman Pharma in Romania.
2023	Entered licensing agreement with Zydus for co-marketing Desidustat in India. US FDA accepted NDA filing for Deuruxolitinib. Sun Pharma Canada launched PR WINLEVI (clascoterone cream 1% w/w) for acne. Entered licensing agreement with Pharmazz Inc. for Tyvalzi (Sovateltide) in India. Launched nationwide initiative Second Birth Date on National Doctor’s Day.
2024	Entered global exclusive commercialization, license, and supply agreement with Philogen for FIBROMUN. Completed acquisition of all outstanding shares of Taro. Included in S&P Global Sustainability Yearbook. Launched STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections.

Client Name	Order Side	QTY	Avg Price	Date
GENESIS EMERGING MARKETS L P	Buy	15858723	816.69	11 Apr 2016
GENESIS INDIAN INVESTMENT COMPANY LIMITED	Sell	15858723	816.69	11 Apr 2016
GENESIS INDIAN INVESTMENT COMPANY LIMITED	Sell	15850000	864.01	14 Mar 2016
GENESIS EMERGING MARKETS L P	Buy	15850000	864.01	14 Mar 2016
GOVERNMENT OF SINGAPORE- C	Buy	12619297	930.16	21 Apr 2015
ARANDA INVESTMENT MAURTIUS PTE LTD	Buy	20161290	930.16	21 Apr 2015
DAIICHI SANKYO COMPANY LIMITED	Sell	214969058	931.58	21 Apr 2015
GOLDMAN SACHS (SINGAPORE) PTE	Buy	51218896	930.16	21 Apr 2015
DEUTSCHE SECURITIES MAURITIUS LIMITED	Buy	997500	1061.65	22 Jun 2007

Sun Pharmaceutical Industries Ltd News

Sun Pharma Q3FY26: Strong Growth with ₹33,688M Profit

Sun Pharmaceutical Industries reported Q3FY26 consolidated revenue of ₹154,690.7 million (up 15.1% YoY) and net profit of ₹33,688.1 million (up 16.0% YoY). Board declared interim dividend of ₹11 per share.

31 Jan 2026

co actions results

Sun Pharma Block Trade Worth ₹278.87 Crores on NSE

Sun Pharmaceutical Industries executed a significant block trade on NSE involving 1,734,892 shares valued at ₹278.87 crores at ₹1607.40 per share, indicating substantial institutional activity.

28 Jan 2026

co actions results

China Halts Sun Pharma Dementia Drug Sales

China has stopped sales of Sun Pharmaceutical's dementia drug following issues identified during a remote inspection by regulatory authorities.

27 Jan 2026

stocks

Sun Pharma Gets Approval for Generic Semaglutide

Sun Pharmaceutical receives regulatory approval to manufacture and sell generic semaglutide injection in India for weight management under brand name NovelTreat with five dose options.

23 Jan 2026

stocks

Sun Pharma Gets Buy Rating with 30% Upside Potential

Jefferies issues Buy call on Sun Pharma with ₹2,100 target price, citing potential benefits from proposed ₹1,30,000 crore Organon acquisition despite leverage concerns and execution risks.

21 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800